Literature DB >> 1731110

Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.

J J de Jong1, J Goudsmit, W Keulen, B Klaver, W Krone, M Tersmette, A de Ronde.   

Abstract

Chimeric human immunodeficiency virus type 1 (HIV-1) molecular clones differing only in the envelope V3 region were constructed. The V3 regions were derived from two HIV-1 isolates with a non-syncytium-inducing, non-T-cell-tropic phenotype and from four HIV-1 isolates with a syncytium-inducing, T-cell-tropic phenotype. When assayed in SupT1 cells, the two chimeric viruses with a V3 region derived from the non-syncytium-inducing isolates did not induce syncytia and showed a low level of replication. The four chimeric viruses with a V3 region derived from the syncytium-inducing isolates did induce syncytia and replicated efficiently in SupT1 cells. In A3.01 cells, which do not support syncytium formation, the V3 loop affected replication similarly. Upon prolonged culture in SupT1 cells, the phenotype of a non-syncytium-inducing, low-replicating chimeric HIV-1 converted into a syncytium-inducing, high-replicating phenotype. Mutations within the usually conserved GPGR tip of the loop, which were shown to be responsible for the conversion into the syncytium-inducing, high-replicating phenotype, had occurred. In vitro mutagenesis showed that coupled changes of amino acids at both sides of the tip of the V3 loop were able to convert the viral phenotype from non-syncytium-inducing, low replicating into syncytium inducing, high replicating. Our data show that the V3 loop is involved in both syncytium forming and replicative capacity of HIV-1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731110      PMCID: PMC240775     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1.

Authors:  J P Langedijk; N K Back; P J Durda; J Goudsmit; R H Meloen
Journal:  J Gen Virol       Date:  1991-10       Impact factor: 3.891

2.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region.

Authors:  T Masuda; S Matsushita; M J Kuroda; M Kannagi; K Takatsuki; S Harada
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

4.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Authors:  K Javaherian; A J Langlois; G J LaRosa; A T Profy; D P Bolognesi; W C Herlihy; S D Putney; T J Matthews
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

5.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

Authors:  C K Leonard; M W Spellman; L Riddle; R J Harris; J N Thomas; T J Gregory
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

6.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals.

Authors:  M Clerici; D R Lucey; R A Zajac; R N Boswell; H M Gebel; H Takahashi; J A Berzofsky; G M Shearer
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

8.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

9.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.

Authors:  L N Callahan; M Phelan; M Mallinson; M A Norcross
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  106 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.

Authors:  Georgios Pollakis; Almaz Abebe; Aletta Kliphuis; Moustapha I M Chalaby; Margreet Bakker; Yohannes Mengistu; Margreet Brouwer; Jaap Goudsmit; Hanneke Schuitemaker; William A Paxton
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle.

Authors:  R A Fouchier; M Brouwer; N A Kootstra; H G Huisman; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

5.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

Authors:  A B van't Wout; N A Kootstra; G A Mulder-Kampinga; N Albrecht-van Lent; H J Scherpbier; J Veenstra; K Boer; R A Coutinho; F Miedema; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

Review 10.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.